Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Forty Seven Inc (FTSV_old)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Forty Seven's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Forty Seven historical data, for real-time data please try another search
95.51 +0.00    +0.00%
06/04 - Closed. Currency in USD ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 95.46 - 95.52
Type:  Equity
Market:  United States
Forty Seven 95.51 +0.00 +0.00%

Forty Seven Company Profile

 
Read the Forty Seven Inc company profile to learn more about the business and the management team. View Forty Seven Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

68

Equity Type

ORD

Forty Seven, Inc., a clinical-stage immuno-oncology company, focuses on developing novel therapies to activate macrophages for the treatment of cancer. It offers magrolimab, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. The company has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin’s lymphoma; and collaboration with Acerta Pharma to evaluate novel immuno-oncology triple combination in diffuse large B-Cell Lymphoma. Forty Seven, Inc. was formerly known as CD47 Sciences, Inc. The company was incorporated in 2014 and is headquartered in Foster City, California. It has locations in North America, South America, Asia, the Middle East, Africa, Australia, and Europe. Forty Seven, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Contact Information

Address 333 Lakeside Drive Suite A
Foster City, 94404
United States
Phone 650 574 3000
Fax 650 578 9264
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

FTSV_old Price Commentary

Write your thoughts about Forty Seven Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email